The clustering of IDH1/ATRX-mutant cases supports the existence of a distinct expression profile, consistent with the biological underpinnings of the IDH-mutant astrocytoma subgroup, as defined in the WHO CNS 2021 classification. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).